Decision Resources and Millennium Research Group have published a new report that finds that companies bringing biologic agents to the increasingly competitive psoriasis market are taking bolder, higher-risk approaches to demonstrating clinical superiority and competing against the established market leader, Amgen/Wyeth/Takeda's Enbrel.

According to the new report entitled Brands & Strategies: Psoriasis, marketers of biologic agents have been reluctant to conduct trials directly comparing the efficacy of their agents with either conventional therapies or competing biologics. However, Abbott recently released data from the CHAMPION trial, a head-to-head comparison of the TNF-alpha inhibitor Humira and the leading conventional therapy, methotrexate. The CHAMPION trial found that a significantly greater proportion of patients responded to therapy with Humira than with methotrexate. Furthermore, a comparison of Centocor's novel interleukin inhibitor CNTO-1275 and market-leading Enbrel is underway.

"Abbott and Centocor are taking bold steps in conducting head-to-head trials," said Matt Runnalls, analyst at Millennium Research Group. "Marketers of leading biologic agents for inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and psoriasis, have shied away from evaluating their products in head-to-head trials. The comparison of CNTO-1275 and Enbrel represents the first such head-to-head comparison of biologics in this therapeutic area."

About Brands & Strategies

Brands & Strategies is the first and only report series to bring together all of the competitive information elements biopharmaceutical companies need to make informed decisions about their products and best next-steps. Each report includes the following:

    * Brand-specific, event-driven, five-year annualized market forecast     * Country-specific market share projections by brand and assessment of       impacts of future events     * Drug class sales by country     * Brand sales by region     * Projected price for all drugs for five years     * Generic pricing impact on all drugs     * Prevalence and diagnosis rates by country     * Promotional spend for each product     * Pipeline analysis by company within a specific disease     * SWOT analysis on each brand     * Clinical trial reviews and clinical trial competitive analysis     * Detailed brand strategy and how it relates to clinical trial results     * Impact of Medicare     * Selling strategies based on clinical trials    About Millennium Research Group 

Millennium Research Group (www.MRG.net), part of the Decision Resources, Inc., family, is a leading provider of strategic information to the healthcare sector. Focused on the medical device, pharmaceutical, and biotechnology industries, the company provides clients its specialized industry expertise through published reports and customized consulting services.

About Decision Resources

Decision Resources, Inc., (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

South Carolina Insurer Goes Global With Medical Tourism Contract

View Now